Plus Therapeutics (PSTV) announced the renewal of its Master Services Agreement with Telix IsoTherapeutics Group. The MSA secures supply of cGMP Re-186, the radioisotope used in Plus Therapeutics lead radiotherapeutic candidate Rhenium Obisbemeda. The company said the agreement: focus on the production of key radionuclide intermediate aluminum perrhenate and the final processing of cGMP Re-186; and enables expanded, scalable, just-in-time manufacturing to support overall supply chain.
Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com